CRISPR Therapeutics AG
Insider activity for last month from Oct 16 to Nov 16.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
CRSP transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|
Sakhamuri SivakesavaChief Technology OfficerCTO | GrantForm 4 code A. Grant, award, or other acquisition under Rule 16b-3(d). | $0View disclosure → | |
Sakhamuri SivakesavaChief Technology OfficerCTO | GrantForm 4 code A. Grant, award, or other acquisition under Rule 16b-3(d). | $0View disclosure → | |
Kulkarni SamarthCEOCEO. Role codes can represent multiple titles; the list does not include the filing title. | GrantForm 4 code A. Grant, award, or other acquisition under Rule 16b-3(d). | $0View disclosure → | |
Kulkarni SamarthCEOCEO. Role codes can represent multiple titles; the list does not include the filing title. | GrantForm 4 code A. Grant, award, or other acquisition under Rule 16b-3(d). | $0View disclosure → | |
Patel NaimishCMOCMO. Role codes can represent multiple titles; the list does not include the filing title. | GrantForm 4 code A. Grant, award, or other acquisition under Rule 16b-3(d). | $0View disclosure → | |
Patel NaimishCMOCMO. Role codes can represent multiple titles; the list does not include the filing title. | GrantForm 4 code A. Grant, award, or other acquisition under Rule 16b-3(d). | $0View disclosure → | |
Silver Andrew JacobChief Financial OfficerCFO | GrantForm 4 code A. Grant, award, or other acquisition under Rule 16b-3(d). | $0View disclosure → | |
Kulkarni SamarthCEOCEO. Role codes can represent multiple titles; the list does not include the filing title. | Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | —View disclosure → | |
Kulkarni SamarthCEOCEO. Role codes can represent multiple titles; the list does not include the filing title. | SellForm 4 code S. Open-market or private sale of a non-derivative or derivative security. | −$2.38MView disclosure → | |
Kulkarni SamarthCEOCEO. Role codes can represent multiple titles; the list does not include the filing title. | Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | —View disclosure → |
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Nov 6, 2026
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Oct 2026 | 0 | 1 | 5 | $0 | $2,381,325.86 | −$2,381,325.86 |
| Nov 2026 | 0 | 0 | 2 | $0 | $0 | $0 |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (3)Largest insider activity
By absolute net disclosed value · current transaction page- SS$0
- PN$0
- SJ$0
- KS—
Filing, role and holdings details
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period- A · Grants / awards · dominant7 · 70%
- M · Option exercise2 · 20%
- S · Open-market sells1 · 10%
Activity by reported role
A joint filing can contribute to multiple rolesReported Holdings After
Separated by insider, security, and ownership type
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redCRISPR Therapeutics AG Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at CRISPR Therapeutics AG?
Sakhamuri Sivakesava, Kulkarni Samarth, Patel Naimish, Silver Andrew Jacob.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Kulkarni Samarth reported a sale on Oct 19, 2026 valued at $2.38M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $2,381,325.86. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.